Stock RXRX RECURSION PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
7.84 USD -1.26% Intraday chart for Recursion Pharmaceuticals, Inc. +5.95% -20.49%
Apr. 18 Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing MT
Apr. 16 Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing
MT
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer
MT
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
GL
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
AQ
Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer
CI
Recursion to Participate in Upcoming Investor Conference
GL
Recursion to Participate in Upcoming Investor Conference
AQ
Recursion Publishes Annual Environmental, Social and Governance Report
GL
Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing
MT
Recursion Pharmaceuticals to Open London Office
MT
Recursion Announces Plans to Open New Office in London
GL
Recursion Announces Plans to Open New Office in London
AQ
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
GL
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
AQ
Recursion to Participate in Upcoming Investor Conferences
GL
Recursion to Participate in Upcoming Investor Conferences
AQ
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat
MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat
MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RXRX Stock
  4. News Recursion Pharmaceuticals, Inc.